Letrozole Tablets

Product description

Letrozole is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery.

Strength: 2.5mg.

Letrozole Tablets have got Chinese local GMP certificate and EU GMP (Spain and  Netherlands), and have MA issued from US-FDA, Japanese PMDA. It was approved by EU and launched in European market in 2012, approved by US FDA and Launched in American market in May, 2013 and approved to get launched in the Japanese market in 2015.
Read more


Categories Finished Dosage FormsTablets; Finished Dosage Forms
Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America

More products from Jiangsu Hengrui Medicine Co., Ltd.

View all our products (78)

Products from other suppliers